 |
 |

Analysis of Colorectal Cancer Stage Among HMO Members Targeted for Screening
Ronald E. Myers, PhD;
James Murray, MD;
David Weinberg, MD;
Gene McGrory, MA;
Thomas Wolf, MA;
Jennifer Caveny;
Nicholas Hanchak, MD;
Neil Schlackman, MD;
Robert Comis, MD
Arch Intern Med. 1997;157(17):2001-2006.
Abstract
 |  |
Background This study is a retrospective analysis of data collected from patient medical records, a fecal occult blood test (FOBT) screening program, and computerized health maintenance organization (HMO) claims and encounters records.
Objective To identify factors associated with a diagnosis of early (Dukes A and B) colorectal cancer among older adults targeted for annual FOBT screening.
Methods Study subjects were insured by the former US Healthcare Inc (Blue Bell, Pa), an independent practice association-type HMO. The HMO was recently integrated into Aetna-US Healthcare. Before diagnosis, subjects were eligible for free annual FOBT screening through the HMO's colorectal cancer screening program. The study subjects included men and women (N=222) who were aged 50 years or older and had a diagnosis of colorectal cancer between 1987 and 1990. Variables considered were patient age, gender, socioeconomic status, medical history, screening history, length of enrollment in the HMO, and stage of disease at diagnosis.
Results Univariate analyses indicate that colorectal cancer diagnosis due to FOBT screening (P=.03), frequency of FOBT screening (P=.09), and length of HMO membership (P=.10) were positively related to being diagnosed as having early stage colorectal cancer. Multivariable analysis shows that having a screen-detected colorectal cancer was significantly and positively related (P=.03) to being diagnosed as having early stage disease.
Conclusions Findings support annual FOBT screening among older adults. Results illustrate the value of applying standard methods to the collection and analysis of patient data in a managed care context. The study also highlights a need for research on patient adherence to screening and physician follow-up of abnormal screening test results.
Arch Intern Med. 1997;157:2001-2006
Author Affiliations
From the Behavioral Epidemiology Section (Dr Myers and Messrs McGrory and Wolf), Gastroenterology Section (Dr Weinberg), and Division of Neoplastic Diseases (Dr Comis), Department of Medicine, Thomas Jefferson University, and US Healthcare Inc (Drs Murray, Hanchak, and Schlackman and Ms Caveny), Philadelphia, Pa.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED LETTER
Colon Cancer Screening: Performance and Payments
Lee Sataline
Arch Intern Med. 1998;158(8):928.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The impact of gender on clinical manifestations of primary antiphospholipid syndrome
Jara et al.
Lupus 2005;14:607-612.
ABSTRACT
Colon Cancer Screening: Performance and Payments
Sataline
Arch Intern Med 1998;158:928-928.
FULL TEXT
Colorectal Cancer Screening: A Stitch in Time . . .
JWatch Women's Health 1997;1997:13-13.
FULL TEXT
Colon Cancer Reduction: Questions About Implementation of Proven Techniques
Marshall et al.
Arch Intern Med 1997;157:1919-1920.
ABSTRACT
|